section name header

Pronunciation

la-MOE-tri-jeen

Classifications

Therapeutic Classification: anticonvulsants

Indications

REMS


Action

  • Stabilizes neuronal membranes by inhibiting sodium transport.
Therapeutic effects:
  • Decreased incidence of seizures.
  • Delayed time to recurrence of mood episodes in bipolar disorder.

Pharmacokinetics

Absorption: 98% absorbed following oral administration.

Distribution: Highly bound to melanin-containing tissues (eyes, pigmented skin).

Metabolism/Excretion: Mostly metabolized by the liver via glucuronidation to inactive metabolites; 10% excreted unchanged by the kidneys.

Half-Life: Children taking enzyme–inducing anticonvulsants: 7–10 hr; Children taking enzyme inducers and valproic acid: 15–27 hr; Children taking valproic acid: 44–94 hr; Adults: 25.4 hr (during chronic therapy of lamotrigine alone).

Time/Action Profile

(plasma concentrations)

ROUTEONSETPEAKDURATION
POunknown1.4–4.8 hr; 4–10 hr (XR)unknown





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Interactions

Drug-drug:

Route/Dosage

Epilepsy

Bipolar Disorder

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

LaMICtal, LaMICtal ODT, LaMICtal XR, Subvenite